Drug Profile
Lepunafusp alfa - JCR Pharmaceuticals
Alternative Names: JR 171Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator JCR Pharmaceuticals
- Class Enzymes; Glycoside hydrolases; Recombinant fusion proteins
- Mechanism of Action Iduronidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Mucopolysaccharidosis I
Most Recent Events
- 06 Oct 2023 Pharmacokinetic, adverse events and efficacy data from a phase I/II trial in Mucopolysaccharidosis I released by JCR Pharmaceuticals
- 29 Sep 2023 Interim efficacy and adverse events data from a phase I/II trial in Mucopolysaccharidosis type I (MPS I) released by JCR Pharmaceuticals
- 27 Feb 2023 Adverse events and efficacy data from a phase I/II trial in Mucopolysaccharidosis I released by JCR Pharmaceuticals